US FDA approves Fortress Bio and Zydus' treatment for a rare pediatric disease
13/01/2026 12:54
Jan 13 (Reuters) - The U.S Food and Drug Administration approved Fortress Biotech FBIO.O and Indian drugmaker Zydus Lifesciences' ZYDU.NS drug for a type of rare genetic disease in children, Fortress said on Tuesday. (Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Devika Syamnath) ((Padmanabhan.Ananthan@thomsonreuters.com;))
Recent news on Fortress Biotech
See all newsFortress Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Fortress Biotech Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Fortress Biotech And Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
Fortress Biotech Q1 net income jumps on PRV sale
Brief: Journey Medical Corporation Secures Contract With Third Major Gpo For Emrosi